3 known cases. View patent page →
Action identified as one of six district-court actions relating to the '501 patent, consolidated with the Barr actions and dismissed without prejudice on May 21, 2010. Whether the '018 patent was separately asserted in this action is unconfirmed.
Celgene action against Lotus and Alvogen over lenalidomide ANDA No. 210480. The narrative states the '018 patent was not listed among the patents challenged; the Rule 12(c) challenge involved the REMS patents '720, '977, '784, '886 and '531. The motion for judgment on the pleadings was denied without prejudice on December 14, 2018.
Consolidated purchaser/insurer antitrust litigation alleging Celgene improperly listed Thalomid/Revlimid distribution-method patents in the Orange Book and pursued sham litigation. The '018 patent is referenced within the distribution-method patent family but is not asserted for infringement.